Spiegel Noel Joseph sold $64K of AEO

BMO Capital raised its price target on American Eagle Outfitters (NYSE:AEO) to $20 from $18, citing strong Aerie brand momentum and improved women's bottoms sales. The stock trades at $17.41 with a P/E ratio of 8.93. BMO expects upside to Q4 gross margin guidance due to lower tariff rates. AEO reported Q2 earnings of $0.79 per share on $1.38 billion revenue, beating estimates. TD Cowen cut its target to $16, while UBS lowered its target to $27 but maintained a Buy rating.

American Eagle Outfitters (AEO) reported Q2 2026 revenue of $1.38B, up 7.5% YoY, with operating income of $211M, boosted by a $161M tariff refund. Excluding this, core operating profit fell 50% YoY. Aerie brand grew 25% YoY, while American Eagle saw 1% revenue growth. Management cut full-year operating income guidance to $540-550M.

American Eagle Outfitters (AEO) reported Q2 2026 sales of $1.38B, net income of $134.08M, and EPS of $0.80. The company issued Q3 and full-year 2026 operating income guidance of $110M-$115M and $540M-$550M, respectively. Analysts highlight execution around inventory, markdowns, and digital productivity as key catalysts, while noting risks from consumer caution and cost pressures. The company declared a quarterly dividend of $0.125 per share.

American Eagle Outfitters (AEO) reported Q2 FY26 revenue of $1.38B, up 8% YoY, with EPS of $0.79. Aerie's sales grew 19%, while American Eagle's fell 1%. Tariff refunds added $161M to operating income. AEO expects FY26 operating income of $540M-$550M, including refunds. Hedge fund ownership declined, with BlackRock as the largest stakeholder.

American Eagle reported Q2 revenue of $1.4B, up 8%, beating expectations. Aerie and OFFLINE segments drove growth, while the core brand faced challenges. Margins were impacted by tariff refunds and markdowns. Analysts trimmed price targets, but the consensus suggests 35% upside. Institutional investors own 98% of the float, showing bullish signs. The core brand's turnaround is a key risk.

Dell shares rose 11% to a record high after RBC initiated coverage with an Outperform rating and $640 target, citing strong AI and PC demand. Apple shares gained 3.1% after unveiling its first foldable iPhone, the iPhone Duo, priced at $1,999 and above. AstraZeneca's shares remained flat despite mixed analyst views on its drug tozorakimab. Compass Pathways shares climbed 4% on positive Phase III study data for its psilocybin treatment.